D. A. Thomas, H. Kantarjian, and T. L. Smith, Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy, Cancer, vol.86, pp.1216-1246, 1999.

E. Tavernier, J. M. Boiron, and F. Huguet, Outcome of treatment after fi rst relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial, Leukemia, vol.21, pp.1907-1921, 2007.

A. K. Fielding, S. M. Richards, and R. Chopra, Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study, Blood, vol.109, pp.944-50, 2007.

A. Oriol, S. Vives, and J. M. Hernández-rivas, Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group, Haematologica, vol.95, pp.589-96, 2010.

N. Gökbuget, D. Stanze, and J. Beck, Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation, Blood, vol.120, pp.2032-2073, 2012.

R. Stein, M. Juweid, M. J. Mattes, and D. M. Goldenberg, Carcinoembryonic antigen as a target for radioimmunotherapy of human medullary thyroid carcinoma: antibody processing, targeting, and experimental therapy with 131 I and 90 Y labeled MAbs, Cancer Biother Radiopharm, vol.14, pp.37-47, 1999.

M. Garcia-barros, F. Paris, and C. Cordon-cardo, Tumor response to radiotherapy regulated by endothelial cell apoptosis, Science, vol.300, pp.1155-59, 2003.

R. M. Sharkey and D. M. Goldenberg, Cancer radioimmunotherapy, Immunotherapy, vol.3, pp.349-70, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01258870

J. M. Burke, J. G. Jurcic, and D. A. Scheinberg, Radioimmunotherapy for acute leukemia, Cancer Control, vol.9, pp.106-119, 2002.

D. Hoelzer and N. Gokbuget, Chemoimmunotherapy in acute lymphoblastic leukemia, Blood Rev, vol.26, pp.25-32, 2012.

S. Raponi, M. S. De-propris, and S. Intoppa, Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases, Leuk Lymphoma, vol.52, pp.1098-107, 2011.

H. Kantarjian, D. Thomas, and J. Jorgensen, Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study, Lancet Oncol, vol.13, pp.403-414, 2012.

R. J. Kreitman and I. Pastan, Antibody fusion proteins anti-CD22 recombinant immunotoxin moxetumomab pasudotox, Clin Cancer Res, vol.17, pp.6398-405, 2011.

J. P. Leonard, M. Coleman, and J. C. Ketas, Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results, Clin Cancer Res, vol.10, pp.5327-5361, 2004.

I. N. Micallef, M. J. Maurer, and G. A. Wiseman, Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diff use large B-cell lymphoma, Blood, vol.118, pp.4053-61, 2011.

E. A. Raetz, M. S. Cairo, and M. J. Borowitz, Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group pilot study, J Clin Oncol, vol.26, pp.3756-62, 2008.

A. S. Advani, S. Mcdonough, and S. Coutre, SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia, Br J Haematol, vol.165, pp.504-513, 2014.

J. Carnahan, R. Stein, and Z. Qu, Epratuzumab, a CD22-targeting recombinant humanized antibody with a diff erent mode of action from rituximab, Mol Immunol, vol.44, pp.1331-1372, 2007.

F. Morschhauser, F. Kraeber-bodere, and W. A. Wegener, High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma, J Clin Oncol, vol.28, pp.3709-3725, 2010.

F. Kraeber-bodéré, A. Pallardy, L. Gouill, and S. , Consolidation anti-CD22 fractionated radioimmunotherapy with 90 Y-epratuzumab tetraxetan following R-CHOP in elderly DLBCL patients: a LYSA phase II prospective trial, Blood, vol.120, p.906, 2012.

G. L. Griffi-ths, S. V. Govindan, R. M. Sharkey, D. R. Fisher, and D. M. Goldenberg, 90 Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma, J Nucl Med, vol.44, pp.77-84, 2003.

L. Ferrer, E. Malek, and C. Bodet-milin, Comparisons of dosimetric approaches for fractionated radioimmunotherapy of non-Hodgkin lymphoma, Q J Nucl Med Mol Imaging, vol.56, pp.529-566, 2012.

R. D. Blumenthal, W. Lew, M. Juweid, R. Alisauskas, Z. Ying et al., Plasma FLT3-L levels predict bone marrow recovery from myelosuprressive therapy, Cancer, vol.88, pp.333-376, 2000.

J. M. Bertho, C. Demarquay, and J. Frick, Level of FLT3-ligand in plasma: a possible new bio-indicator for radiation-induced aplasia, Int J Radiat Biol, vol.77, pp.703-715, 2001.

P. Chevallier, C. Bodet-milin, and N. Robillard, BCR-ABL1 molecular remission after 90 Y-epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B-ALL: proof of principle, Eur J Haematol, vol.91, pp.552-56, 2013.

R. M. Sharkey, A. Brenner, and J. Burton, Radioimmunotherapy of non-Hodgkin's lymphoma with 90 Y-DOTA humanized anti-CD22

. Igg, Y-epratuzumab): do tumor targeting and dosimetry predict therapeutic response?, J Nucl Med, vol.44, issue.90, pp.2000-2018, 2003.

M. T. Milano, L. S. Constine, and P. Okunieff, Normal tissue toxicity after small fi eld hypofractionated stereotactic body radiation, Radiat Oncol, vol.3, p.36, 2008.

F. M. Uckun and C. W. Song, Lack of CD24 antigen expression in B-lineage acute lymphoblastic leukemia is associated with intrinsic radiation resistance of primary clonogenic blasts, Blood, vol.81, pp.1323-1355, 1993.

H. W. Findley, L. Gu, A. M. Yeager, and M. Zhou, Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia, Blood, vol.89, pp.2986-93, 1997.

S. Han, J. C. Brenner, and A. Sabolch, Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition, Neoplasia, vol.15, pp.1207-1224, 2013.

J. Barbet, M. Bardiès, and M. Bourgeois, Radiolabeled antibodies for cancer imaging and therapy, Methods Mol Biol, vol.907, pp.681-97, 2012.

F. Morschhauser, J. Radford, and A. Van-hoof, 90 Yttrium-ibritumomab tiuxetan consolidation of fi rst remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7·3 years from the International, Randomized, Phase III First-Line Indolent trial, J Clin Oncol, vol.31, pp.1977-83, 2013.

T. E. Witzig, M. B. Tomblyn, and J. G. Misleh, , p.22

, Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma, Haematologica, vol.99, pp.1738-1783, 2014.